Cardiosonix' Quantix/OR Product Cleared for Marketing In Europe.

Business Editors/Health/Medical Writers

DUBLIN, Ohio--(BUSINESS WIRE)--Jan. 23, 2003

Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that its wholly owned subsidiary Cardiosonix, Ltd. received clearance to begin marketing of the Quantix/OR(TM) in Europe.

The Quantix/OR received CE mark clearance to begin marketing for the intraoperative measurement of blood flow in various surgical settings. Neoprobe expects to begin commercial shipment of the first Quantix/OR systems to certain European markets this quarter. The Quantix/OR is the second Cardiosonix' ADBF(TM) product in the Quantix family to receive CE Mark clearance.

David Bupp, Neoprobe's president, said, "The CE mark clearance to market represents another sequential achievement of a commercial milestone consistent with the objectives that we outlined twelve months ago at the time of the acquisition of Cardiosonix. We believe the Quantix/OR will be the cornerstone product for the ADBF technology and will serve as the platform for innovating the way blood flow measurement is viewed by the medical community. The receipt of the CE mark clearance will allow us to achieve wider evaluation of the Quantix/OR in clinical sites in Europe. We expect to begin shipment of the Quantix/OR to distributors in Europe in the next few weeks. In addition, we are in the process of preparing the submission of the 510(k) application to the United States Food and Drug Administration."

The Quantix/OR system includes a control unit and two Doppler probes that can measure blood flow in vessels of various sizes. The Quantix/OR can be used during coronary or other by-pass procedures to determine graft patency or it can be used prior to the harvesting of a native artery for a by-pass procedure to ascertain quality of flow. The Quantix/OR is based upon Cardiosonix' proprietary ADBF technology and measures blood flow volume based upon the traditional definition.

Cardiosonix' first product, the Quantix/ND(TM) is used for the non-invasive measurement of blood flow in neurosurgery and received regulatory clearances for marketing in the United States and Europe in late 2002. Neoprobe began shipments of the Quantix/ND to distributors in Europe during the fourth quarter of 2002.

About Neoprobe

Neoprobe develops and provides innovative surgical and diagnostic products that enhance patient care by meeting the critical decision making needs of healthcare professionals. Neoprobe's current line of gamma detection systems is widely used for intraoperative lymphatic mapping (ILM), an emerging standard of care technology for breast cancer and melanoma and detection of radiopharmaceuticals applied throughout the human body's tissues and organs. Neoprobe also holds significant interests in the development of related biomedical systems and agents. The Company's strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. With the December 31, 2001 acquisition of Cardiosonix Ltd., Neoprobe has expanded its product portfolio to include blood flow measurement products. Cardiosonix is a development stage company that is in the process of obtaining regulatory clearance to begin the clinical evaluation and commercial sale of products. Cardiosonix' products are designed to be used by neurosurgeons, cardiovascular surgeons and critical care physicians.

Statements in this news release which relate to other than strictly historical facts are forward-looking statements, and as such are subject to risks and uncertainties, including those detailed in the Company's most recent Annual Report on Form 10-KSB and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.